Deciphera pharmaceuticals, inc. (DCPH)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Revenues

25,062

25,000

25,000

0

0

-

0

-

0

0

0

0

0

Operating expenses:
Research and development

173,209

157,610

138,330

118,586

101,751

82,887

71,189

60,310

50,780

39,514

0

0

0

Selling, general, and administrative

0

-

-

-

0

-

-

-

-

-

-

-

-

Selling, general, and administrative

-

-

50,853

38,133

-

21,212

19,418

16,589

14,380

11,421

0

0

0

Total operating expenses

252,025

225,726

189,183

156,719

131,173

104,099

90,607

76,899

65,160

50,935

0

0

0

Loss from operations

-226,963

-200,726

-164,183

-131,719

-131,173

-104,099

-90,607

-76,899

-65,160

-50,935

0

0

0

Other income (expense):
Interest and other income, net

9,338

8,537

6,919

6,220

5,440

4,329

3,227

1,918

1,247

746

0

0

0

Interest expense

54

67

75

79

75

84

87

89

92

95

0

0

0

Total other income (expense), net

9,284

8,470

6,844

6,141

5,365

4,245

3,140

1,829

1,155

651

0

0

0

Net loss

-217,716

-192,300

-157,385

-125,624

-125,854

-99,900

-87,483

-75,086

-64,021

-50,300

0

0

0

Net loss per share—basic and diluted (in dollars per share)

-1.36

-1.39

-1.28

-0.56

-1.25

-0.86

-0.65

-0.65

-0.66

-0.38

-1.04

-0.91

-0.66

Weighted average common shares outstanding—basic and diluted (in shares)

53,567

51,415

43,803

38,200

38,057

37,746

37,654

33,567

32,594

32,289

11,626

11,626

11,626

Comprehensive loss:
Net loss

-217,716

-192,300

-157,385

-125,624

-125,854

-99,900

0

0

0

-

-

-

-

Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities

742

111

61

0

0

-

0

-

-

-

-

-

-

Total other comprehensive income (loss)

742

111

61

0

0

-

0

-

-

-

-

-

-

Total comprehensive loss

-216,937

-192,145

-157,278

-125,403

-125,787

-99,854

0

0

0

-

-

-

-